| http://dbpedia.org/ontology/abstract
|
Als Decarboxylasehemmer (auch Decarboxylas … Als Decarboxylasehemmer (auch Decarboxylase-Hemmstoffe, DDCI bzw. DDI (DOPA-Decarboxylase-Inhibitor)) werden in der Medizin pharmakologische Wirkstoffe bezeichnet, die das Enzym DOPA-Decarboxylase inhibieren. Sie werden bei der Behandlung des Morbus Parkinson zusammen mit Levodopa eingesetzt. Dieses Kombinationsprinzip ist grundsätzlich seit 1960 bekannt, heute gilt die alleinige Gabe von Levodopa als obsolet, d. h. nicht mehr zeitgemäß. Es sind heute fünf Hemmstoffe der DOPA-Decarboxylase bekannt:
* Benserazid – DL-Serin-2-(2,3,4-trihydroxybenzyl)-hydrazid
* Carbidopa – (−)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrozimtsäure
* L-Serin-2-(2,3,4-trihydroxybenzyl)-hydrazid
* Glycin-2-(2,3,4-trihydroxybenzyl)-hydrazid
* L-Tyrosin-2-(2,3,4-trihydroxybenzyl)hydrazid Trotzdem finden im Wesentlichen nur Benserazid und Carbidopa in verschiedenen Kombipräparaten medizinische Verwendung.n Kombipräparaten medizinische Verwendung.
, Um inibidor de L-aminoácido aromático desc … Um inibidor de L-aminoácido aromático descarboxilase ou inibidor da descarboxilase dos L-aminoácidos aromáticos (com os sinônimos inibidor da DOPA decarboxilase abreviado em inglês, DDCI, de DOPA decarboxylase inhibitor, e AAADI, de aromatic L-amino acid decarboxylase inhibitor) é uma droga que inibe a síntese de dopamina pela enzima L-aminoácido aromático descarboxilase (AADC, AAAD, ou DOPA decarboxilase), uma enzima piridoxina dependente, responsável pela conversão da L-dopa em dopamina, e 5 hidroxitriptofano em serotonina. A deficiência desse enzima, é resultante de erro inato do metabolismo dos neurotransmissores, resultando numa doença autossômica recessiva que causa manifestações neurológicas graves. Estes agentes farmacologicamente ativos são utilizados no tratamento da doença de Parkinson juntamente com a levodopa. Este princípio de combinação tem sido conhecido em princípio desde 1960 Hoje, a administração única de levodopa é considerada obsoleta. única de levodopa é considerada obsoleta.
, An aromatic L-amino acid decarboxylase inh … An aromatic L-amino acid decarboxylase inhibitor (synonyms: DOPA decarboxylase inhibitor, Extracerebral decarboxylase inhibitor, DDCI and AAADI) is a medication of type enzyme inhibitor which inhibits the synthesis of dopamine by the enzyme aromatic L-amino acid decarboxylase (AADC, AAAD, or DOPA decarboxylase). It is used to inhibit the decarboxylation of L-DOPA to dopamine outside the brain, i.e. in the blood. This is primarily co-administered with L-DOPA to combat Parkinson's disease. Administration can prevent common side-effects, such as nausea and vomiting, as a result of interaction with D2 receptors in the vomiting center (or cheomoreceptor trigger zone) located outside the blood–brain barrier. Examples of extracerebral decarboxylase inhibitors include carbidopa and benserazide.ibitors include carbidopa and benserazide.
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Levodopa_pathway.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
18708932
|
| http://dbpedia.org/ontology/wikiPageLength
|
4286
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1120152176
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Biosynthesis +
, http://dbpedia.org/resource/Carbidopa +
, http://dbpedia.org/resource/Parkinson%27s_disease +
, http://dbpedia.org/resource/Dopamine +
, http://dbpedia.org/resource/Medication +
, http://dbpedia.org/resource/Alpha-Difluoromethyl-DOPA +
, http://dbpedia.org/resource/Augmentation_%28pharmacology%29 +
, http://dbpedia.org/resource/Therapy +
, http://dbpedia.org/resource/Enzyme +
, http://dbpedia.org/resource/Methyldopa +
, http://dbpedia.org/resource/Blood +
, http://dbpedia.org/resource/D2_receptors +
, http://dbpedia.org/resource/Category:Aromatic_L-amino_acid_decarboxylase_inhibitors +
, http://dbpedia.org/resource/EGCG +
, http://dbpedia.org/resource/File:Levodopa_pathway.svg +
, http://dbpedia.org/resource/Aromatic_L-amino_acid_decarboxylase +
, http://dbpedia.org/resource/Epigallocatechin +
, http://dbpedia.org/resource/Adverse_effect +
, http://dbpedia.org/resource/Blood%E2%80%93brain_barrier +
, http://dbpedia.org/resource/Benserazide +
, http://dbpedia.org/resource/Enzyme_inhibitor +
, http://dbpedia.org/resource/L-DOPA +
, http://dbpedia.org/resource/Peripherally_selective_drug +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Enzyme_inhibition +
, http://dbpedia.org/resource/Template:Dopamine_receptor_modulators +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Adrenergic_receptor_modulators +
, http://dbpedia.org/resource/Template:Antiparkinson_agents +
, http://dbpedia.org/resource/Template:Redirect +
, http://dbpedia.org/resource/Template:Nervous-system-drug-stub +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Aromatic_L-amino_acid_decarboxylase_inhibitors +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Drug +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Aromatic_L-amino_acid_decarboxylase_inhibitor?oldid=1120152176&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Levodopa_pathway.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Aromatic_L-amino_acid_decarboxylase_inhibitor +
|
| owl:sameAs |
http://sr.dbpedia.org/resource/Inhibitor_aromati%C4%8Dne_L-aminokiselinske_dekarboksilaze +
, http://de.dbpedia.org/resource/Decarboxylasehemmer +
, http://www.wikidata.org/entity/Q4795512 +
, http://dbpedia.org/resource/Aromatic_L-amino_acid_decarboxylase_inhibitor +
, http://pt.dbpedia.org/resource/Inibidor_de_L-amino%C3%A1cido_arom%C3%A1tico_descarboxilase +
, http://yago-knowledge.org/resource/Aromatic_L-amino_acid_decarboxylase_inhibitor +
, http://sh.dbpedia.org/resource/Inhibitor_aromati%C4%8Dne_L-aminokiselinske_dekarboksilaze +
, http://rdf.freebase.com/ns/m.04y5m86 +
, https://global.dbpedia.org/id/4RvGm +
|
| rdf:type |
http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Inhibitor114724436 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Substance100020090 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/WikicatAAADInhibitors +
|
| rdfs:comment |
Um inibidor de L-aminoácido aromático desc … Um inibidor de L-aminoácido aromático descarboxilase ou inibidor da descarboxilase dos L-aminoácidos aromáticos (com os sinônimos inibidor da DOPA decarboxilase abreviado em inglês, DDCI, de DOPA decarboxylase inhibitor, e AAADI, de aromatic L-amino acid decarboxylase inhibitor) é uma droga que inibe a síntese de dopamina pela enzima L-aminoácido aromático descarboxilase (AADC, AAAD, ou DOPA decarboxilase), uma enzima piridoxina dependente, responsável pela conversão da L-dopa em dopamina, e 5 hidroxitriptofano em serotonina. A deficiência desse enzima, é resultante de erro inato do metabolismo dos neurotransmissores, resultando numa doença autossômica recessiva que causa manifestações neurológicas graves. Estes agentes farmacologicamente ativos são utilizados no tratamento da doença de Pao utilizados no tratamento da doença de Pa
, Als Decarboxylasehemmer (auch Decarboxylas … Als Decarboxylasehemmer (auch Decarboxylase-Hemmstoffe, DDCI bzw. DDI (DOPA-Decarboxylase-Inhibitor)) werden in der Medizin pharmakologische Wirkstoffe bezeichnet, die das Enzym DOPA-Decarboxylase inhibieren. Sie werden bei der Behandlung des Morbus Parkinson zusammen mit Levodopa eingesetzt. Dieses Kombinationsprinzip ist grundsätzlich seit 1960 bekannt, heute gilt die alleinige Gabe von Levodopa als obsolet, d. h. nicht mehr zeitgemäß. Es sind heute fünf Hemmstoffe der DOPA-Decarboxylase bekannt:Hemmstoffe der DOPA-Decarboxylase bekannt:
, An aromatic L-amino acid decarboxylase inh … An aromatic L-amino acid decarboxylase inhibitor (synonyms: DOPA decarboxylase inhibitor, Extracerebral decarboxylase inhibitor, DDCI and AAADI) is a medication of type enzyme inhibitor which inhibits the synthesis of dopamine by the enzyme aromatic L-amino acid decarboxylase (AADC, AAAD, or DOPA decarboxylase). It is used to inhibit the decarboxylation of L-DOPA to dopamine outside the brain, i.e. in the blood. This is primarily co-administered with L-DOPA to combat Parkinson's disease. Administration can prevent common side-effects, such as nausea and vomiting, as a result of interaction with D2 receptors in the vomiting center (or cheomoreceptor trigger zone) located outside the blood–brain barrier.) located outside the blood–brain barrier.
|
| rdfs:label |
Inibidor de L-aminoácido aromático descarboxilase
, Aromatic L-amino acid decarboxylase inhibitor
, Decarboxylasehemmer
|
